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Role of the microenvironment for radiosensitization by
patupilone 
Abstract
Purpose: The combined treatment modality of ionizing radiation and the clinically relevant
microtubule-stabilizing compound patupilone (epothilone B, EPO906) is a promising approach for
anti-cancer therapy. Here we investigated the role of the tumor microenvironment for the supra-additive
in vivo response in tumor xenografts derived from patupilone-sensitive and patupilone resistant
non-small cell lung cancer cells. Experimental Design: The treatment response to a combined regimen
of patupilone and ionizing radiation was investigated in vitro and in tumor xenografts derived from
wildtype A549 and A549.EpoB40 cells which are resistant to patupilone due to a β-tubulin mutation.
Results: In both A549 and A549.EpoB40 cells proliferative activity and clonogenicity were reduced in
response to ionizing radiation, while patupilone, as expected, inhibited proliferation of the mutant cell
line with reduced potency. Combined treatment with patupilone and ionizing radiation induced a
cytotoxic effect in an additive way in the A549, but not in the tubulin-mutated, patupilone-resistant
A549.EpoB40 cells. A supra-additive tumor growth delay was induced by combined treatment in
xenografts derived from A549 cells, but not in xenografts derived from A549.EpoB40 cells. Histological
analysis revealed a significant decrease in tumor cell proliferation and microvessel density and a
treatment-dependent increase or decrease in tumor hypoxia only in A549 xenografts. Conclusions:
Using a genetically defined patupilone-sensitive and resistant tumor model we here demonstrated that
the major cytotoxic effect of the combined treatment modality of IR and patupilone is directed against
the tumor cell compartment. The induced anti-angiogenic effect derives indirectly from the tumor cell.  
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 Statement of Clinical Relevance 
 
Patupilone is a novel microtubule inhibitor with known antitumor and anti-angiogenic activity 
currently in phase II/III clinical trials. Herein, we present first complementary in vitro and in 
vivo results investigating the role of the tumor microenvironment for the treatment response 
to the  promising combined treatment modality of ionizing radiation with the clinically 
relevant microtubule inhibitor patupilone, especially in taxane-refractory and P-glycoprotein-
overexpressing tumors. 
Using a genetically-defined patupilone-sensitive and patupilone-resistant tumor model system 
we here demonstrate that the major cytotoxic effect of the combined treatment modality of IR 
and patupilone is directed against the tumor cell compartment and that the induced anti-
angiogenic effect, which contributes to the synergistic treatment response of this combined 
treatment modality, derives indirectly from the tumor cell. These preclinical experiments are 
of relevance for clinical strategies that target the microtubule cytoskeleton and HIF 
dysregulation  in combination with ionizing radiation.   
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 Abstract 
Purpose: The combined treatment modality of ionizing radiation and the clinically relevant 
microtubule-stabilizing compound patupilone (epothilone B, EPO906) is a promising 
approach for anti-cancer therapy. Here we investigated the role of the tumor 
microenvironment for the supra-additive in vivo response in tumor xenografts derived from 
patupilone-sensitive and patupilone resistant non-small cell lung cancer cells. 
Experimental Design: The treatment response to a combined regimen of patupilone and 
ionizing radiation was investigated in vitro and in tumor xenografts derived from wildtype 
A549 and A549.EpoB40 cells which are resistant to patupilone due to a β-tubulin mutation. 
Results: In both A549 and A549.EpoB40 cells proliferative activity and clonogenicity were 
reduced in response to ionizing radiation, while patupilone, as expected, inhibited 
proliferation of the mutant cell line with reduced potency. Combined treatment with 
patupilone and ionizing radiation induced a cytotoxic effect in an additive way in the A549, 
but not in the tubulin-mutated, patupilone-resistant A549.EpoB40 cells. A supra-additive 
tumor growth delay was induced by combined treatment in xenografts derived from A549 
cells, but not in xenografts derived from A549.EpoB40 cells. Histological analysis revealed a 
significant decrease in tumor cell proliferation and microvessel density and a treatment-
dependent increase or decrease in tumor hypoxia only in A549 xenografts. 
Conclusions: Using a genetically defined patupilone-sensitive and resistant tumor model we 
here demonstrated that the major cytotoxic effect of the combined treatment modality of IR 
and patupilone is directed against the tumor cell compartment. The induced anti-angiogenic 
effect derives indirectly from the tumor cell.  
 3
 Introduction 
Interference with microtubule function is a promising strategy for anti-cancer therapy (1). 
This approach has been extensively validated by the use of taxanes (microtubule-stabilizers) 
for the treatment of a wide variety of human malignancies. The suppression of microtubule 
dynamics interferes with mitotic spindle formation, leading to cell cycle arrest in M-phase and 
eventually to apoptosis or post-mitotic cell death. The primary mechanism of microtubule 
stabilizing agents (MSA) at the biochemical level is well investigated, but the signaling 
consequences relevant for their cytotoxic effect are far from clear. Furthermore, treatment 
with taxanes (paclitaxel, docetaxel) is limited by taxane-related toxicities and the 
development of multidrug-resistance. This has prompted an ongoing worldwide search for 
novel microtubule-targeting compounds. One new class of microtubule stabilizing agents  are 
the epothilones, which are structurally distinct from the taxanes and may overcome some of 
their limitations suggesting a promising  new treatment approach for cancer (2-4). 
Epothilones are non-taxoid MSA of bacterial origin which share the same binding site on β-
tubulin with taxanes (5, 6). One of the epothilones, patupilone (epothilone B, EPO906), is 
currently in phase-II clinical development in a number of different solid tumors and is in 
phase-III clinical trials for ovarian cancers in patients refractory to carboplatin-taxane 
treatment. Patupilone retains activity against P-glycoprotein-expressing multi-drug resistant 
cells both in vitro and in vivo (5) and shows different clinical toxicities to the taxanes (6, 7). 
Apart from the direct tumor-cytotoxic action, patupilone has also demonstrated anti-vascular 
(8) and anti-angiogenic effects (9). The anti-angiogenic effect might be linked to different 
mechanisms, either directly targeting endothelial cells (10) or indirectly interfering with the 
secretion of pro-angiogenic agents from tumor cells (11, 12).  
The accumulation of cells in the most radiosensitive G2-M phase of the cell cycle represents 
the current rationale to combine microtubule stabilizing agents with ionizing radiation and 
promises a strong radiosensitizing effect in combination with ionizing radiation (IR) (2, 13, 
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 14). Our own previous in vitro and in vivo experiments performed with patupilone in 
combination with IR demonstrated an at least additive cytotoxic effect in various cancer cell 
types in vitro and strong supra-additivity of the combined treatment regimen against tumor 
xenografts in vivo. Interestingly, also a S-phase progression-related mechanism for 
radiosensitization was observed (15). 
The observed in vivo supra-additive response to patupilone in combination with IR points to 
an additional mechanism of sensitization which is not limited to the tumor cell, but which 
may also be due to effects on the microenvironment within the solid tumor (15).  
Here we investigated the different treatment modalities of patupilone and IR alone and in 
combination in vitro and in vivo using a patupilone-sensitive A549 cell line and the mutant 
derivative cell line (A549.EpoB40), which is strongly resistant to patupilone in vitro since it 
contains a defined β-tubulin-mutation (3, 11, 16, 17). In this manner we aimed to distinguish 
between a tumor cell and/or tumor microenvironment-directed effect of the different treatment 
modalities. Our results demonstrate a major tumor cell directed effect with a subsequent 
indirect anti-angiogenic effect especially by the combined treatment modality of patupilone in 
combination with IR.  
 
Materials and Methods 
Patupilone (epothilone B, EPO906) was provided by the chemistry department of Novartis 
Pharma AG (Basel, Switzerland). The human cell line pair A549 and A549.EpoB40 was 
obtained from the laboratory of Dr. SB Horwitz. 
Cell cultures, drug preparation and irradiation. The human non-small cell lung cancer lines 
A549 and A549.EpoB40 were grown in RPMI 1640 containing 10% (v/v) fetal bovine serum, 
1% (v/v) penicillin-streptomycin and 1% (v/v) L-glutamine at 37º in 5% CO2. A549.EpoB40 
is derived from A549 by stepwise selection with patupilone and contains a point mutation in 
class 1 β-tubulin (β292 from Gln to Glu) which is associated with a ~95-fold resistance to 
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 patupilone (3). The A549.EpoB40 cell line was grown and maintained in medium containing 
10 nM EPO906. For in vitro experiments, patupilone was dissolved in DMSO (1 mM stock 
solution) and further diluted with media containing 10% FCS.  
Irradiation of cell cultures was carried out using a Pantak Therapax 300 kV X-ray unit at 70 
cGy/min at room temperature. For combined treatment, the cells were pretreated with 
patupilone 18 hours before irradiation. 
 
Cell proliferation and clonogenic survival assays. The proliferative activity of tumor cells 
was assessed in 96-well plates with the colorimetric alamarBlue assay that is based on 
detection of metabolite activity according to the protocol of the manufacturer (Biosource 
International, Camarillo, CA). Absorption was measured at 570 and 630 nm using a Tecan 
GENios spectrophotometer. Experiments were carried out under normoxic as well as hypoxic 
conditions. To render cells hypoxic, cells were grown in a hypoxic incubator at 1% pO2. 
Clonogenic survival was determined by the ability of single cells to form colonies in vitro. 
The number of plated cells was adjusted to obtain ~100 colonies per cell culture dish with a 
given treatment. After treatment with different regimes, the dishes were maintained at 37º in 
5% CO2 and allowed to grow for 12 days before fixation in methanol/acetic acid (3:1) and 
staining with crystal violet. Colonies with >50 cells/colony were counted manually. All assays 
were repeated as independent experiments at least thrice.  
 
Tumor xenograft in nude mice and application of treatment regimes. A549 or 
A549.EpoB40 cells (4 x 106) were injected subcutaneously on the back of 4- to 8-week old 
athymic nude mice. Tumor volumes were determined from caliper measurements of tumor 
length (L) and width (l) according to the formula (L x l2)/2. Tumors were allowed to expand to 
a volume of 200 mm3 (± 10%) before treatment start. Using a customized shielding device 
mice were given a strictly loco-regional radiotherapy of 4 x 3 Gy or 3 x 1 Gy at 4 or 3 
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 consecutive days using a Pantak Therapax 300 kV X-ray unit at 0.7 Gy/min. Patupilone 
(dissolved in 30% PEG-300 / 70% saline) was applied i.v. 24h prior to the first treatment with 
IR (at day 0 of the treatment). Tumor growth was monitored at least thrice and body weight 
once weekly.  
 
Histology, immunohistochemistry. Tissues were immersion-fixed in 4% PBS buffered 
formalin and embedded in paraffin. Three-micron thick sections were mounted on glass slides 
(SuperFrost Plus; Menzel, Braunschweig, Germany), deparaffinized, rehydrated and stained 
with haematoxylin and eosin using standard histological techniques. In addition, CC1 (antigen 
retrieval solution; Ventana Medical Systems, Tucson, AZ) pretreated sections were 
immunostained for Ki-67 (rabbit clone SP6; dilution 1:100; NeoMarkers, Fremont, CA, 
USA), CD31 (rabbit polyclonal, ab28364; dilution 1:50; Abcam, Cambridge, UK) and GLUT-
1 (rabbit polyclonal, MYM AB 1351; dilution 1:1000; Chemicon International, Temecula, 
CA, USA) using a Discovery immunohistochemistry staining system (Ventana Medical 
Systems). Detection of primary antibody was performed with a biotinylated anti-rabbit IgG 
antibody (Jackson ImmunoResearch, West Grove, PA) and the iView DAB kit (Ventana 
Medical Systems). For hypoxia detection, pimonidazole hydrochloride (60-80 mg/kg) was 
applied intravenously 45 minutes before sacrifice. CC1 pretreated sections were incubated 
with Hypoxyprobe-1 MAb1 (mouse IgG1, dilution 1:300; Chemicon International, Temecula, 
CA) conjugated with fluoresceinisothiocyanat (FITC). Detection of primary antibody was 
performed with a biotinylated mouse anti-FITC antibody (Jackson ImmunoResearch) and the 
iView DAB kit. All immunostains were counterstained with hematoxylin. 
To determine proliferative activity, Ki67-positive tumor cells were counted in 5 to 10 
randomly chosen visual fields (magnification x200) in each xenogaft (n=4 for each group) 
The mean Ki67 positive cell count from these fields was determined. Microvessel density 
(MVD) was determined in 5 to 10 randomly chosen visual fields (high power fields, HPF) in 
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 each of three equally treated vital tumor tissues at x 100 magnification (0.3 mm2 visual field 
size). Hypoxia staining was quantified by manual counting using a grid of 1200 points in two 
photographs per tumor, which displayed the whole tumor section. 
Transfections and reporter gene assay. Both cell lines were stably transfected with a vector 
construct containing two copies of the VEGF hypoxia response element and SV40-promoter 
in front of the luciferase gene. Stably, hygromycin-selected A549 and A549.EpoB40 cell lines 
were tested for luciferase enzymatic activity with a commercial kit (Bright-Glo™ luciferase 
assay, Promega Corporation, Madison, WI, USA) using a GloMax™ 20/20 Luminometer. 
Hypoxic conditions were mimicked using Dimethyloxaloylglycine (DMOG) (Biomol GmbH, 
Hamburg, Germany), a prolyl-4-hydroxylase inhibitor, which prevents HIF degradation at 
priorly tested non-toxic concentrations of 0.25 and 1 mM, respectively. To discriminate 
between treatment-induced cell death and treatment-interfered HIF-signaling cells were 
transiently co-transfected with a Renilla luciferase expressing control vector. Patupilone was 
applied 24 h after transient transfection. DMOG treatment was started 24 h and irradiation 
(5Gy) 28 h after patupilone treatment. Luciferase activity was determined 14 h after treatment 
with DMOG.   
 
Statistical analysis. Statistical analysis of the in vivo tumor growth data was performed with 
the Mann-Whitney U test. The absolute tumor growth delay was defined as the time for tumor 
volume in the treated groups to triplicate the initial treatment size minus the time in the 
untreated control group to reach the same size. Kruskal-Wallis one-way analysis of variance 
was used to test for significant differences of Ki67, CD31 and hypoxia following the various 
treatments. Treatments effects (difference between control and treatments) were analysed  
using the Mann-Whitney U test. The level of significance was set at 0.05; the calculations 
were all done using the StatView program [SAS Institute Inc.] version 5.0.1. 
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 Results 
Antiproliferative effect of patupilone under normoxic and hypoxic conditions. The 
antiproliferative effect of patupilone was tested over 72 hours in the A549 wildtype and the 
A549.EpoB40 mutant cell line under normoxic and hypoxic conditions. A dose dependent 
decrease of the proliferative activity was observed in the A549 tumor cells (IC50 ~0.2 nM), 
while a more than 100 fold higher concentration (>20 nM) was required to obtain the same 
antiproliferative effect in the mutant A549.EpoB40 cell line. No difference with regard to the 
antiproliferative effect by patupilone was observed under normoxia and under hypoxia (1% 
pO2) (Fig 1A, B). 
 
Antiproliferative and clonogenic cell death-inducing effect by combined treatment with 
patupilone and IR. The antiproliferative effect of patupilone in combination with IR was 
tested using increasing concentrations of patupilone and doses of IR. In the patupilone-
sensitive A549 cell line an additive antiproliferative effect was induced with 5 Gy, a dose that 
shows less than 50% inhibition of proliferation over 72 hours in response to irradiation alone 
(Fig 2A, B). No radiosensitizing effect could be detected in the drug resistant A549.EpoB40 
cell line at various doses of patupilone and IR. Interestingly these cells were also slightly 
more radioresistant than the wildtype counterpart cell line (Fig 2C, D). Patupilone was also 
highly potent against human umbilical vein endothelial cells (HUVEC). Picomolar 
concentrations of patupilone were sufficient to inhibit endothelial cell proliferation and cell 
viability alone and in combination with IR (data not shown). Clonogenic survival assays were 
performed with both cell lines and increasing concentrations of patupilone and IR. 
Clonogenicity was reduced in an at least additive way in the A549 cell population. In contrast, 
the mutant cell line A549.EpoB40 was refractory to patupilone alone up to 10 nM, and 
patupilone did not sensitize for IR (Fig 2 E, F). 
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 Effect of combined treatment with patupilone and IR on growth of tumor xenografts. We 
previously observed a supra-additive effect of a combined patupilone/IR treatment on tumor 
growth delay in xenografts derived from radioresistant SW480 human colon adenocarcinoma 
cells (15). In the tumor xenografts derived from the wildtype A549 cell line, a small growth 
delay was induced by 3 x 1 Gy irradiation compared with untreated control tumors. Growth 
was significantly inhibited by patupilone (1 x 2 mg/kg) treatment alone (p=0.022). In 
response to the combined treatment modality a supra-additive tumor growth delay was 
observed. Tumor growth in the combined treatment group was significantly inhibited 
compared to IR or patupilone treated groups (p=0.010, p=0.013) (Fig 3A). The absolute 
growth delay to triple the initial tumor volume at the start of treatment (200 mm3 ± 10%) was 
most enhanced with the combined treatment modality when compared with the absolute 
tumor growth delay in response to patupilone or IR alone [26 days (patupilone + IR) versus 6 
days (patupilone) and 2 days (IR)], respectively (data not shown). In contrast no tumor growth 
delay was induced by the same dose of patupilone in tumors derived from the drug resistant 
A549.EpoB40 cells, indicating that the tumor growth suppression effect of patupilone 
primarily derives from tumor cell-directed cytotoxicity (Fig 3B). The tumors derived from the 
mutated cell line were also more radiation resistant than the wildtype counterparts. 
Nevertheless a treatment regimen of 4 x 3 Gy alone induced a significant growth delay in 
tumors derived from these cells (p=0.004). On the other hand combined treatment did not 
further increase the antitumor effect, and even a slightly diminished absolute tumor growth 
delay was observed after combined treatment versus treatment with IR alone [14 days (IR) 
versus 9 days (patupilone + IR), not shown)]. These results indicate that the major antitumor 
effect of the investigated treatment modality derives from tumor cell directed cytotoxicity. A 
direct anti-angiogenic effect of patupilone alone or in combination with irradiation is unlikely 
to contribute to the observed tumor growth delay. Determination of body weight changes only 
revealed a minor patupilone-dependent transient weight-loss over 48 hours after treatment 
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 initiation. No skin changes or tissue damage were observed in the co-irradiated healthy tissue 
area around the tumor. 
 
Histological analysis of treatment-induced effects in tumor xenografts. To investigate a 
putative anti-angiogenic effect of the different treatment modalities, microvessel density, 
tumor hypoxia and the proliferative status were determined in tumor sections of treated mice, 
which were collected 84 h after treatment with patupilone (2 mg/kg) or vehicle alone, after 
fractionated irradiation (3 x 1 Gy or 3 x 3 Gy, respectively) or the combined treatment 
modality. Histological analysis was first performed on xenografts without any treatment to 
compare baseline characteristics of A549 and A549.EpoB40 xenografts. Xenografts of both 
A549 and A549.EpoB40 cells showed solid growth of carcinoma cells with areas of necrosis 
and thin stromal septa.  
Tumor cell proliferation was determined using immunohistochemistry for the Ki-67 protein, 
which is expressed during all phases of the cell cycle except G0. In the tumors derived from 
the drug sensitive A549 cell line, the proliferative activity was reduced by 32% 84 hours after 
treatment with patupilone alone, while irradiation and the combined treatment reduced the 
proliferative activity by 54% and 71%, respectively (p<0.0001). No change in the 
proliferative activity could be detected in A549.EpoB40 derived tumor sections after 
patupilone treatment. Irradiation reduced the proliferative activity by 22% (p<0.0001), 
without any further effect in the combined treatment group (Fig. 4A, B). To examine the 
effect of the different treatment modalities on the tumor vasculature, microvessel density 
(MVD) was determined by CD31 immunohistochemistry. Patupilone reduced the MVD in the 
drug-sensitive tumors by 25% at the 84h time point when compared to control tumors 
(p=0.0003). Irradiation and combined treatment reduced the MVD by 37% and 47%, 
respectively (p<0.0001). In the drug-resistant tumors a tendency in MVD-reduction was only 
observed in the irradiated group (p=0.074) (Fig. 4C , D). 
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 Treatment-induced changes of the tumor vasculature may also affect the pO2 in the tumor 
tissue. We therefore determined treatment-dependent changes of tumor oxygenation by 
injection of the hypoxia probe pimonidazole, which specifically accumulates in hypoxic tissue 
areas. Treatment-dependent changes of hypoxic areas were determined in histological sections 
84 h after treatment. A significant increase of pimonidazole accumulation was determined in 
A549-derived tumors after treatment with patupilone (p=0.0019), while the amount of 
hypoxic, pimonidazole-positive areas was reduced in the irradiated group (p=0.0045). 
Interestingly, the amount of hypoxic areas was similar to untreated tumors after treatment 
with patupilone in combination with IR (p=0.747). No change of pimonidazole accumulation 
was observed in any of the treatment groups in A549.EpoB40-derived tumor sections (Fig. 4E 
F). These results indicate that changes in the tumor microenvironment in response to the 
different treatment modalities mainly derive from the treatment effect directed against the 
tumor cells (see below).  
 
Treatment-interfered expression of hypoxia-induced gene expression. The hypoxia-
inducible factor (HIF) represents the major determinant in tumor cells for hypoxia-regulated 
expression of pro-angiogenic factors and patupilone reduced the level of the  hypoxia 
sensitive HIF-1α subunit under hypoxic conditions in the patupilone sensitive A549 cell line 
as determined by western blotting (data not shown). Using a luciferase-based reporter gene 
assay under control of multiple hypoxia-response elements, the treatment response of 
patupilone and ionizing radiation alone and in combination was quantitatively assessed in the 
patupilone-sensitive and –resistant cell lines. To normalize for transfection efficacy and cell 
numbers, cells were co-transfected with the renilla luciferase expressing vector system. To 
mimic hypoxic conditions cells were incubated in Dimethyloxaloylglycine (DMOG) thereby 
upregulating the endogenous HIF-level and inducing luciferase-expression 8.5-fold over 
control conditions (data not shown). Treatment of the patupilone-sensitive A549 cells with 
 12
 increasing doses of the microtubule stabilizing agent significantly reduced luciferase 
expression already at subnanomolar concentrations (p= 0.010). Of note the A549.EpoB40 
cells were resistant up to low nanomolar concentrations of patupilone (20 nM) indicating a 
role of microtubule-interference in HIF-1α regulated gene expression (Fig 5A). Treatment of 
cells with increasing doses of irradiation only minimally affected luciferase expression (data 
not shown). Treatment with increasing doses of patupilone in combination with IR (5 Gy) 
additionally decreased luciferase-expression (p=0.018) in the A549 cell line indicating a 
synergistic stress response on the level of hypoxia-regulated gene expression (Fig. 5B).  
 
Discussion 
Here we investigated the treatment response of tumor xenografts derived from a MSA-
sensitive and a MSA-resistant lung adenocarcinoma cell line to treatment with patupilone and 
ionizing radiation alone or in combination. We previously identified a strong treatment 
response to this combined treatment modality in vivo in the SW480 human colon xenograft 
model which strongly exceeded the additive cytotoxic effect of the treatment combination in 
vitro (15). By means of this genetically-defined tumor model we now were able to 
differentiate between a direct tumor cell-directed and a microenvironment-directed cytotoxic 
in vivo effect in response to the different treatment modalities. 
We observed a cytotoxic and tumor growth delay effect in the tumors derived from the MSA-
sensitive adenocarcinoma cell line A549 in response to irradiation and patupilone alone and a 
supra-additive response to combined treatment. As expected, patupilone reduced the 
proliferative activity of the MSA-resistant cell line A549.EpoB40 in vitro only at more than 
100-fold the concentration necessary for the wildtype cell line (3, 18). As determined here in 
this report, no tumor growth delay could be observed in vivo with treatment of patupilone 
alone and no enhancement of an IR-effect was induced on combined treatment in tumors 
derived from the MSA-resistant cell line. Of note, patupilone induced an anti-angiogenic 
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 response with reduced microvessel density and enhanced hypoxia on in the wildtype but not 
in the MSA-resistant tumors.  
The wildtype A549 cell line was also more sensitive to treatment with increasing doses of 
ionizing radiation than A549.EpoB40 cells which carry a specific Gln to Glu mutation at 
residue 292 in the M-loop of β-tubulin and which changes the affinity of β-tubulin to the 
microtubule-stabilizing agent (3). We cannot exclude that additional mutations are present in 
the patupilone-resistant cells, but most likely the known β-tubulin mutation not only reduces 
the affinity to patupilone but also affects microtubule dynamics which may subsequently 
render the cells more radiation resistant. Importantly, the proliferative activity and growth 
kinetics of untreated cells or tumors derived from the two different cell lines were similar. An 
increased radiation resistance was present in the patupilone resistant tumor cells and not in the 
sensitive ones and thus still enabled to investigate the involvement of the tumor 
microenvironment in response to the combined treatment modality of ionizing radiation with 
patupilone. 
The potent anti-angiogenic activity of microtubule-stabilizing agents was proposed to be a 
major mechanism leading to the successful anticancer activity of this class of compounds (9, 
11, 19, 20). Patupilone has an anti-proliferative and apoptosis-inducing effect in 
microvascular and macrovascular endothelial cells (9) and our own in vitro experiments 
performed with primary human umbilical vein endothelial cells confirmed the high potency of 
patupilone against this cell type (data not shown). Patupilone also induces vascular disruption 
leading to reduced tumor blood volume (8). We previously demonstrated an at least additive 
antitumor effect by the combined treatment of IR with different inhibitors of angiogenesis, 
such as the VEGF-receptor tyrosine kinase inhibitor PTK787 or the dual RTK-inhibitor 
AEE788 (21, 22). Based on the putative direct anti-angiogenic property of patupilone, a 
partial tumor growth delay effect was expected on treatment with patupilone alone or in 
combination with IR even in tumors derived from the patupilone-resistant tumor cells 
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 A549.Epo40. However treatment with neither patupilone alone nor in combination with IR 
reduced tumor growth or increased tumor growth delay, respectively, in A549.Epo40-derived 
tumors.  
A strong reduction in microvessel density and change in tumor hypoxia on treatment with 
patupilone alone was only detected in tumors derived from the A549-wildtype cells and not in 
tumors derived from the patupilone-resistant tumor cells. Despite direct in vitro cytotoxicity 
against endothelial cells (9), our results indicate that the anti-angiogenic effect of patupilone 
in vivo is indirectly induced by interference on the level of the tumor cellular stress response. 
Our in vitro experiments performed with the hypoxia-regulated reporter gene assay clearly 
demonstrated that patupilone reduces the expression of the HIF-1 “transcriptome” such as 
VEGF and other genes involved in angiogenesis and hypoxic adaptation, but only in 
patupilone sensitive tumor cells, thereby leading to an indirect tumor cell-mediated anti-
angiogenic effect of patupilone. Patupilone might also directly target the microtubule system 
in the tumor endothelial cell compartment, but might be less cytotoxic in presence of 
sufficient VEGF and other survival factors secreted from the tumor cells. The radiosensitivity 
of the tumor vascular network codetermines the tumor response to ionizing radiation (23). 
Therefore pharmacological approaches which interfere with the survival signaling of 
endothelial cells render these cells more radiosensitive and subsequently enhance the tumor 
response to ionizing radiation.  
A major obstacle for the successful tumor response to ionizing radiation is tumor hypoxia 
which renders tumor cells 2-3 times more radioresistant than under normoxic conditions. Of 
note, our in vitro experiments revealed that patupilone is as potent against tumor cells under 
normoxic as under hypoxic conditions. Thus a combined treatment modality of patupilone in 
combination with ionizing radiation also bears promise against tumors with an increased 
hypoxic fraction. Here we observed an increase of tumor hypoxia induced by patupilone 
alone, presumably through this anti-angiogenic, indirect MVD-reducing effect. We previously 
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 investigated the dynamics of tumor hypoxia in response to inhibitors of angiogenesis alone 
and in combination with ionizing radiation and observed that irradiation counteracts the risk 
of treatment-induced hypoxia by the inhibition of angiogenesis (21, 22). While treatment with 
the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 also increased overall and 
local tumor hypoxia, combined treatment with IR resulted in extended tumor growth delay 
and tumor cell apoptosis but no increase in tumor hypoxia (22). As the radiosensitivity of the 
tumor vascular network codetermines the tumor response to ionizing radiation (23), 
pharmacological approaches, which interfere with the survival signaling of endothelial cells, 
render these cells more radiosensitive and subsequently enhance the tumor response to 
ionizing radiation. The reduction of survival factors secreted by the tumor cells, after 
treatment with patupilone, leaves the endothelial cells more vulnerable to direct irradiation. 
Nevertheless combined treatment of patupilone with radiation did not enhance tumor hypoxia 
relative to untreated tumors as if radiation antagonizes the patupilone-induced increase of 
tumor hypoxia. The mechanisms underlying this antagonistic effect is unclear, but it is 
conceivable that enhanced cell death together with reduced proliferation of tumor cells may 
reduce the intratumoral oxygen demand to a level that can still be met by the damaged tumor 
vasculature and thereby avoid a hypoxic state in the allograft (24, 25). This mechanism might 
be relevant for the combined treatment of irradiation with direct and indirect inhibitors of 
angiogenesis.  
In summary, our results using in vivo tumor models derived from patupilone sensitive and 
resistant variants of the non-small cell lung cancer cell line A549, strongly suggests that the 
major anti-tumor effect of patupilone and a combined patupilone/IR treatment is mainly due 
to directed effects on the tumor cell compartment, and that patupilone may induce an anti-
angiogenic effect in an indirect way through tumor cell targeting. Overall, these preclinical 
experiments are of strong relevance for a clinical strategy and further support the promising 
treatment modality of patupilone alone and in combination with ionizing radiation. 
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 Figures and legends 
 
 
Fig. 1. Antiproliferative effect of patupilone under normoxia and hypoxia. Lung 
adenocarcinoma cells A549 (A) and mutant cells A549.EpoB40 (B) were exposed to 
increasing concentrations of patupilone and grown in normoxic or hypoxic conditions 
(1%) for 72 hours. Data were pooled from three independent experiments, columns: 
mean; bars: ± SE. 
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Fig. 2. Antiproliferative effect of patupilone alone and in combination with IR (5 Gy). Lung 
adenocarcinoma cells A549 (A, B) and mutant cells A549.EpoB40 (C, D) were 
exposed to increasing concentrations of patupilone and IR. Clonogenic survival after 
treatment with patupilone and IR was determined for A549 cells (E) and mutant 
A549.EpoB40 cells (F) treated with patupilone 18 h before irradiation.  
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Fig. 3. The effect of patupilone and IR alone or in combination on the growth of A549 (A) and 
A549.EpoB40-derived xenografts in nude mice (B). Mice were treated with patupilone 
(2 mg/kg once) and IR (3 x 1 or 4 x 3 Gy on consecutive days) alone and in 
combination, with administration of patupilone or the vehicle 24 h prior to the first 
fraction of IR. The horizontal bar indicates days of treatment. Each curve represents 
the mean tumor volume per group ± SE.  
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Fig. 4. Tumor cell proliferation, microvessel density and changes in tumor hypoxia in 
response to treatment. Mice with A549 (A, C, E) and A549.EpoB40-derived 
xenografts (B, D, F) were treated with vehicle,  patupilone (2 mg/kg), IR (3 x 1 Gy 
and 3 x 3 Gy, respectively) or a combination of  patupilone and IR. Mice were 
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 sacrificed 84 h after treatment and tumors were harvested, formalin fixed, and stained 
for the Ki-67 (A, B), CD31 as marker of tumor cell proliferation and microvessel 
density (C, D) and antibodies against the exogenous hypoxia marker pimonidazole 
hydrochloride for the immunohistochemical detection of tumor hypoxia (E, F), 
respectively. Each bar represents the mean value per group ± SE, and significance at 
p<0.01 or p<0.001 is indicated by an asterix and double asterix, respectively. 
 
 
 
Fig. 5. Patupilone reduces HRE-dependent cytokine expression. A549 and A549.EpoB40 
cells, stably transfected with a pGL 4.27-HRE-vector (3 x HRE-VEGFpromoter for 
firefly-luciferase expression) and the pRL SV40 vector (renilla luciferase) were  
treated with increasing doses of patupilone (A) and in combination with IR (5 Gy) (B) 
under normal and hypoxia mimicking conditions. The cells were tested for luciferase 
reporter activity 24 hours after patupilone treatment. Each bar represents the mean 
value per group ± SE and significance at p<0.01 or p<0.001 is indicated by an asterix 
and double asterix, respectively. 
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